## Valeant Pharmaceuticals Announces Management Change

March 02, 2016

LAVAL, Quebec, March 2, 2016 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today confirmed that Deb Jorn has resigned as Executive Vice President, Company Group Chairman, effective immediately. In this role, she was responsible for running the company's U.S. Dermatology and Gastrointestinal businesses. Eric Abramson, Vice President Dermatology & Immunology Marketing, has been appointed General Manager of the U.S. Dermatology business and Dr. Ari Kellen, Executive Vice President and Company Group Chairman will oversee Valeant's gastrointestinal business.

## **About Valeant**

Valeant Pharmaceuticals International, Inc. (NYSE/TSX:VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, gastrointestinal disorder, eye health, neurology and branded generics. More information about Valeant can be at www.valeant.com

## **Contact Information:**

Laurie W. Little 949-461-6002 laurie.little@valeant.com

Elif McDonald 905-695-7607

elif.mcdonald@valeant.com

Media:

Renée E. Soto/Meghan Gavigan Sard Verbinnen & Co. 212-687-8080 rsoto@sardverb.com /

mgavigan@sardverb.com

To view the original version on PR Newswire, visit:

http://www.prnewswire.com/news-releases/valeant-pharmaceuticals-announces-management-change-300230063.html

SOURCE Valeant Pharmaceuticals International, Inc.

Page 1 of 2





LEGAL NOTICE PRIVACY POLICY Investor Inquiries

<u>ir@bauschhealth.com</u>

877-281-6642

514-856-3855 (Canada)

<u>Corporate.communications@bauschhealth.com</u>

EMAIL ALERTS

EMAIL PAGE

**RSS FEED** 

Use of this site signifies your agreement to the Legal Notice and Privacy Policy. ©2025 Bausch Health Companies Inc. All rights

reserved. MTB.0230.USA.18 V2.0

908-569-3692

Media inquiries

CALIFORNIA RESIDENTS: <u>DO NOT SELL MY</u>

<u>PERSONAL INFORMATION</u>

